Q1 Scientific expands European operations with 4,000 sq m stability and GDP storage extension in Belgium
Q1 Scientific, a Cambrex company and a leading provider of ICH‑compliant stability storage and GDP‑certified pharmaceutical storage services, today announced a significant expansion of its Belgian operations following the signing of a long‑term lease agreement with FOXACO. The newly added 4,000 sq m of temperature‑controlled stability storage, GDP storage, and modern office space, significantly increases Q1 Scientific’s capacity to support Europe’s rapidly growing pharmaceutical, biotech, and clinical research sector.
This investment marks another major milestone for Q1 Scientific’s operations in Villers‑le‑Bouillet, and reflects the continued strategic commitment of Cambrex to expand life sciences infrastructure and capabilities across key global regions.
Supporting Europe’s clinical and commercial supply chains
The expansion enhances Q1 Scientific’s ability to support both clinical trials and commercial manufacturers by adding substantial additional GDP‑certified storage capacity for investigational medicinal products and finished pharmaceutical goods. Products destined for hospitals, pharmacies, and distributors throughout Belgium and continental Europe will now benefit from increased secure, compliant, end‑to‑end temperature‑controlled storage capacity.
With purpose‑built storage chambers ranging from ‑80°C to +40°C, the expanded site will accommodate long‑term, accelerated, and intermediate stability studies, alongside secure commercial storage and disaster recovery services for emergency situations.
Commenting on the expansion, Cécile Jacoby, Administratrice-Déléguée of Q1 Scientific SRL in Villers-le-Bouillet said:
This expansion represents a major step forward for Q1 Scientific in Belgium and for the life sciences community in Wallonia. With an additional 4,000 sq m, we are significantly increasing our capacity to support both clinical and commercial supply chains with high-quality, GDP-compliant storage.
Villers-le-Bouillet is rapidly becoming a vibrant hub for pharmaceutical and biotech activity, and we are proud to continue investing here. The support from FOXACO and the broader local ecosystem has been instrumental, and this growth positions us to serve our customers even more effectively across Belgium and the wider European market.
Stephen Delaney, Managing Director of the Q1 Scientific Group, added:
Q1 Scientific continues to invest in Belgium because of the exceptional talent base, robust logistics infrastructure, and dynamic life sciences community here. This expansion demonstrates our long‑term commitment to the region and our confidence in the future of Q1 Scientific’s operations in Belgium.
By increasing our stability and GDP storage footprint, we are strengthening our ability to support global pharmaceutical companies with reliable, compliant, and scalable capacity exactly where they need it.
New office space available for sub-lease to growing life science companies
A portion of the newly developed office space will be made available for sub‑lease to SMEs, start‑ups, and service providers seeking to establish a presence within the Villers‑le‑Bouillet life sciences cluster. This initiative aims to attract emerging companies, foster collaboration, and further enrich the growing local ecosystem.
This sub-lease opportunity supports high‑growth companies that benefit from proximity to pharmaceutical logistics, temperature‑controlled services, academic partnerships, and clinical supply chain networks.
Continued investment in Belgium
Since joining Cambrex in 2022, Q1 Scientific has expanded across Ireland, Belgium, and the United States as part of a multi‑year strategy to build a transatlantic network of harmonised stability and GDP storage services. The Belgian facility remains a key part of this strategy, serving customers across Europe and supporting the region’s growing pipeline of pharmaceutical, biotech, and advanced therapy programmes.
About Q1 Scientific, a Cambrex company
Q1 Scientific, a Cambrex company, is a leading provider of ICH‑compliant stability storage and GDP‑certified temperature‑controlled storage solutions. With facilities in Ireland, Belgium, and the United States, Q1 Scientific supports pharmaceutical, biotech, and medical device companies worldwide through dependable, transparent, and fully compliant storage infrastructure.
Contact our team to learn more.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.
With over 40 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, material characterization, and highly potent APIs.